title: [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
abstract: OBJECTIVE
  The use of anthracyclines are limited by their cardiotoxic side effects (first of all congestive cardiomyopathy). In this study we analyzed the anthracycline-induced cardiotoxicity and the possible preventive role of dexrazoxane in children.
  
  
  METHODS
  158 anthracycline-treated long-term survivors could be analyzed. Sixty-one children received dexrazoxane (group D) and 97 patients received anthracyclines only (group C).
  
  
  METHODS
  Cardiac ultrasound examinations (ECHO) and electrocardiograms (ECG) were performed regularly from the beginning of chemotherapy and yearly thereafter. Shortening fraction (FS) was used as indicator of the ventricular function.
  
  
  RESULTS
  The incidence of reduced left ventricular function (FS) was 13.4% in C, and 8.2% in D (p=ns). Two years after completion of the chemotherapy FS was reduced in 13.7% in C and 0% in D, respectively (p=0.056), and 5 years after therapy in 11.0% in C and 2.4% in D, respectively (P=0.034). Left chamber wall diameter was abnormal in systole in 6% in C and 2% in D, in diastole in 11% in C and 7% in D (p=ns) after 3 years of follow-up.
  
  
  CONCLUSIONS
  Anthracycline-induced subacute cardiotoxicity can be significantly diminished by the concomitant use of dexrazoxane. For the final conclusions longer follow-up is necessary.
authors.affiliation: II. sz. Gyermekklinika, Semmelweis Egyetem, Budapest 1094, Hungary.
authors.forename: Hajna
authors.initials: H
authors.lastname: Erlaky
authors.forename: Kornélia
authors.initials: K
authors.lastname: Tóth
authors.forename: Judit
authors.initials: J
authors.lastname: Szabolcs
authors.forename: Erzsébet
authors.initials: E
authors.lastname: Horváth
authors.forename: Viktória
authors.initials: V
authors.lastname: Kemény
authors.forename: Judit
authors.initials: J
authors.lastname: Müller
authors.forename: Mónika
authors.initials: M
authors.lastname: Csóka
authors.forename: László
authors.initials: L
authors.lastname: Jókúti
authors.forename: Dániel
authors.initials: D
authors.lastname: Erdélyi
authors.forename: Gábor
authors.initials: G
authors.lastname: Kovács
mesh_terms: D000293:Adolescent; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008297:Male; D011929:Razoxane / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D002316:Cardiotonic Agents; D011929:Razoxane